Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Basit Öğe Kaydı
dc.authorid0000-0002-2756-8646
dc.contributor.authorBilici, Ahmet
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorSezer, Ahmet
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorCubukcu, Erdem
dc.date.accessioned2025-05-10T19:27:40Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Clin Oncol
dc.description.sponsorshipRoche Pharmaceuticals
dc.description.sponsorshipRoche Pharmaceuticals.
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7030
dc.identifier.volume40
dc.identifier.wosWOS:000863680302513
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleReal-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu